Zenith Epigenetics’ experienced research team has developed a cutting-edge epigenetic platform, generating differentiated, potent, and selective BET inhibitors. Our experienced management team and world-leading clinical collaborators are developing BETi combination therapies for multiple oncology indications. With a strong emphasis on translational medicine – for selecting patients that will benefit most from the therapy – Zenith is a leader in innovative clinical development of epigenetic combination therapies.
Our lead BETi, ZEN-3694, is in Phase 2 clinical development for the treatment of prostate cancer and breast cancer, the latter in collaboration with Pfizer.
